Llobet-Navàs Lab Publications

  • 2023

    • Generation and Integrated Analysis of Advanced Patient-Derived Orthoxenograft Models (PDOX) for the Rational Assessment of Targeted Therapies in Endometrial Cancer.

      Devis-Jauregui L, Vidal A, Plata-Peña L, Santacana M, García-Mulero S, Bonifaci N, Noguera-Delgado E, Ruiz N, Gil M, Dorca E, Llobet FJ, Coll-Iglesias L, Gassner K, Martinez-Iniesta M, Rodriguez-Barrueco R, Barahona M, Marti L, Viñals F, Ponce J, Sanz-Pamplona R, Piulats JM, Vivancos A, Matias-Guiu X, Villanueva A, Llobet-Navas D.

      Advanced Science. 10:e2204211. 2023 [pubmed]

    • Oxidative stress-induced FAK activation contributes to uterine serous carcinoma aggressiveness.

      Lopez-Mejia IC, Pijuan J, Navaridas R, Santacana M, Gatius S, Velasco A, Castellà G, Panosa A, Cabiscol E, Pinyol M, Coll L, Bonifaci N, Peña LP, Vidal A, Villanueva A, Gari E, Llobet-Navas D, Fajas L, Matias-Guiu X, Yeramian A.

      Molecular Oncology. 17:98-118. 2023 [pubmed]

  • 2022

    • A microRNA Cluster Controls Fat Cell Differentiation and Adipose Tissue Expansion By Regulating SNCG.

      Rodríguez-Barrueco R, Latorre J, Devis-Jáuregui L, Lluch A, Bonifaci N, Llobet FJ, Olivan M, Coll-Iglesias L, Gassner K, Davis ML, Moreno-Navarrete JM, Castells-Nobau A, Plata-Peña L, Dalmau-Pastor M, Höring M, Liebisch G, Olkkonen VM, Arnoriaga-Rodríguez M, Ricart W, Fernández-Real JM, Silva JM, Ortega FJ, Llobet-Navas D.

      Advanced Science. 13:e2104759. 2022 [pubmed]

    • Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation.

      Gámez-Chiachio M, Molina-Crespo Á, Ramos-Nebot C, Martinez-Val J, Martinez L, Gassner K, Llobet FJ, Soriano M, Hernandez A, Cordani M, Bernadó-Morales C, Diaz E, Rojo-Sebastian A, Triviño JC, Sanchez L, Rodríguez-Barrueco R, Arribas J, Llobet-Navas D, Sarrió D, Moreno-Bueno G.

      Journal of Experimental & Clinical Cancer Research. 41:285. 2022 [pubmed]

    • Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program.

      Jiménez C, Antonelli R, Nadal-Ribelles M, Devis-Jauregui L, Latorre P, Solé C, Masanas M, Molero-Valenzuela A, Soriano A, Sánchez de Toledo J, Llobet-Navas D, Roma J, Posas F, de Nadal E, Gallego S, Moreno L, Segura MF.

      Molecular Cancer. 21:175. 2022 [pubmed]

    • A compound directed against S6K1 hampers fat mass expansion and mitigates diet-induced hepatosteatosis.

      Lluch A, Veiga SR, Latorre J, Moreno-Navarrete JM, Bonifaci N, Nguyen VD, Zhou Y, Horing M, Liebisch G, Olkkonen VM, Llobet-Navas D, Thomas G, Rodriguez-Barrueco R, Fernández-Real JM, Kozma SC, Ortega FJ.

      JCI Insight. 7:e150461. 2022 [pubmed]

    • Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer.

      Gatius S, Jove M, Megino-Luque S, Albertí-Valls M, Yeramian A, Bonifaci N, Piñol M, Santacana M, Pradas I, Llobet-Navas D, Pamplona R, Matías-Guiu X, Eritja N.

      Cancers. 14:2842. 2022 [pubmed]

    • ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma.

      Megino-Luque C, Sisó P, Mota-Martorell N, Navaridas R, de la Rosa I, Urdanibia I, Albertí-Valls M, Santacana M, Pinyol M, Bonifaci N, Macià A, Llobet-Navas D, Gatius S, Matias-Guiu X, Eritja N.

      Molecular Oncology. 16:2235-2259. 2022 [pubmed]

  • 2021

    • miR-424/503 modulates Wnt/β-catenin signaling in the mammary epithelium by targeting LRP6.

      Nekritz EA, Rodriguez-Barrueco R*, Yan KK, Davis ML, Werner RL, Devis-Jauregui L, Mukhopadhyay P, Yu J, Llobet-Navas D*, Silva J*.

      EMBO Reports. 22:e53201. 2021 [pubmed]

    • Autophagy in the physiological endometrium and cancer.

      Devis-Jauregui L, Eritja N, Davis ML, Matias-Guiu X, Llobet-Navas D.

      Autophagy. 17:1077-1095. 2021 [pubmed]

    • The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models.

      Masanas M, Masiá N, Suárez-Cabrera L, Olivan M, Soriano A, Majem B, Devis-Jauregui L, Burgos-Panadero R, Jiménez C, Rodriguez-Sodupe P, Boloix A, Toledano I, Guillén G, Navarro A, Llobet-Navas D, Villanueva A, Sánchez de Toledo J, Roma J, Noguera R, Moreno L, Krauss R, Gallego S, Santamaria A, Segura MF.

      Clinical and Translational Medicine. 11:e533. 2021 [pubmed]

    • Neuronal Differentiation-Related Epigenetic Regulator ZRF1 Has Independent Prognostic Value in Neuroblastoma but Is Functionally Dispensable In Vitro.

      Jiménez C, Antonelli R, Masanas M, Soriano A, Devis-Jauregui L, Camacho J, Magdaleno A, Guillén G, Hladun R, Jubierre L, Roma J, Llobet-Navas D, Sánchez de Toledo J, Moreno L, Gallego S, Segura MF.

      Cancers. 13:4845. 2021 [pubmed]

    • Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition).

      Klionsky DJ, et al.

      Autophagy. 17:1-382. 2021 [pubmed]

  • 2018

    • The number of titrated microRNA species dictates ceRNA regulation.

      Chiu HS, Martínez MR, Komissarova EV, Llobet-Navas D, Bansal M, Paull EO, Silva J, Yang X, Sumazin P, Califano A.

      Nucleic Acids Research. 46:4354-4369. 2018 [pubmed]

    • Stems Cells and Cancer.

      Davis M, Gassner K, Rodriguez-Barrueco R, Llobet-Navas D

      Stem Cell Genetics for Biomedical Research. pp 271-309. 2018 [link]

  • 2017

    • Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer.

      Eritja N, Chen BJ, Rodriguez-Barrueco R, Santacana M, Gatius S, Vidal A, Marti MD, Ponce J, Bergada L, Yeramian A, Encinas M, Ribera J, Reventos J, Boyd J, Villanueva A, Matias-Guiu X, Dolcet X, Llobet-Navas D

      Autophagy. 13:608-24. 2017 [pubmed]

    • The miR-424(322)/503 is a breast cancer tumor suppressor that promotes resistance to chemotherapy.

      Rodriguez-Barrueco R, Nekritz EA, Bertucci F , Yu J, Sanchez-Garcia F, Zeleke TZ, Gorbatenko A, Birnbaum D, Ezhkova E, Cordon-Cardo C, Finetti P, Llobet-Navas D*, Silva JM*

      Genes & Development. 31:553-566. 2017 [pubmed]

    • A SMAD3-PTEN auto-regulatory loop controls proliferation and apoptotic responses to TGF-β.

      Eritja N, Felip I, Dosil MA, Vigezzi L, Mirantes C, Yeramian A, Santacana M, Llobet-Navas D, Yoshimura A, Nomura M, Matias-Guiu X, Dolcet X

      Cell Death and Differentiation. 24:1443-1458. 2017 [pubmed]

    • Endometrial Carcinoma: Specific Targeted Pathways.

      Eritja N, Yeramian A, Chen BJ, Llobet-Navas D, Ortega E, Colas E, Abal M, Dolcet X, Reventos J, Matias-Guiu X

      Advances in Experimental Medicine and Biology. 943:149-207. 2017 [pubmed]

    • Immunohistochemical analysis of T-type calcium channels in acquired melanocytic nevi and melanoma.

      Maiques O, Macià A, Moreno S, Barceló C, Santacana M, Vea A, Chen BJ, Llobet-Navas D, Herreros J, Gatius S, Ortega E, Valls J, Matias-Guiu X, Cantí C, Marti RM

      British Journal of Dermatology. 176:1247-1258. 2017 [pubmed]

  • 2016

    • Overexpression of JARID1B promotes differentiation via SHIP1/AKT signaling in human hypopharyngeal squamous cell carcinoma.

      Zhang J, An X, Han Y, Ma R, Yang K, Zhang L, Chi J, Li W, Llobet-Navas D, Xu Y, Jiang Y

      Cell Death and Disease. 7:e2358. 2016 [pubmed]

  • 2015

    • Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks.

      Chiu HS*, Llobet-Navas D*, Yang X, Chung WJ, Ambesi-Impiombato A, Iyer A, Kim HR, Seviour EG, Luo Z, Sehgal V, Moss T, Lu Y, Ram P, Silva J, Mills GB, Califano A, Sumazin P

      Genome Research. 25:257-67. 2015 [pubmed]

    • Inhibition of the autocrine IL6-JAK2-STAT3-Calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.

      Rodriguez-Barrueco R, Yu J, Saucedo-Cuevas LP, Olivan M, Llobet-Navas D, Putcha P, Castro V, Murga-Penas EM, Collazo-Lorduy A, Castillo-Martin M, Alvarez M, Cordon-Cardo C, Kalinsky K, Maurer M, Califano A, Silva JM

      Genes & Development. 29:1631-48. 2015 [pubmed]

    • HDAC6 activity is a non-oncogene addiction hub for in inflammatory breast cancers.

      Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M, Castro V, Llobet-Navas D, Birnbaum D, Finetti P, Woodward WA, Bertucci F, Alpaugh ML, Califano A, Silva J

      Breast Cancer Research. 17:149. 2015 [pubmed]

  • 2014

    • The microRNA 424/503 cluster reduces CDC25A expression during cell cycle arrest imposed by transforming growth factor β in mammary epithelial cells.

      Llobet-Navas D*, Rodriguez-Barrueco R, de la Iglesia-Vicente J, Olivan M, Castro V, Saucedo- Cuevas L, Marshall N, Putcha P, Castillo-Martin M, Bardot E, Ezhkova E, Iavarone A, Cordon- Cardo C, Silva JM*

      Molecular and Cellular Biology. 34:4216-31. 2014 [pubmed]

    • The miR-424(322)/503 cluster orchestrates remodeling of the epithelium in the involuting mammary gland.

      Llobet-Navas D, Rodríguez-Barrueco R, Castro V, Ugalde AP, Sumazin P, Jacob-Sendler D, Demircan B, Castillo-Martín M, Putcha P, Marshall N, Villagrasa P, Chan J, Sanchez-Garcia F, Peer D, Rabadán R, Iavarone A, Cordón-Cardó C, Califano A, López-Otín C, Ezhkova E, Silva JM

      Genes & Development. 28:765-82. 2014 [pubmed]

    • Integration of Genomic Data Enables Selective Discovery of Breast Cancer Drivers.

      Sanchez-Garcia F, Villagrasa P, Matsui J, Kotliar D, Castro V, Akavia UD, Chen BJ, Saucedo- Cuevas L, Rodriguez Barrueco R, Llobet-Navas D, Silva JM, Peer D

      Cell. 159:1461-75. 2014 [pubmed]

    • A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia..

      Herranz D, Ambesi-Impiombato A, Palomero T, Schnell SA, Belver L, Wendorff AA, Xu L, Castillo- Martin M, Llobet-Navas D, Cordon-Cardo C, Clappier E, Soulier J, Ferrando AA

      Nature Medicine. 20:1130-7. 2014 [pubmed]

  • ≤ 2013

    • Long-term Estradiol Exposure Is a Direct Mitogen for Insulin/EGF-Primed Endometrial Cells and Drives PTEN Loss-Induced Hyperplasic Growth.

      Eritja N, Mirantes C, Llobet D, Yeramian A, Bergadà L, Dosil MA, Domingo M, Matias-Guiu X, Dolcet X

      American Journal of Pathology. 183:277-87. 2013

    • TNFR- associated factor 2 deficiency in B lymphocytes predisposes to chronic lymphocytic leukemia/small lymphocytic lymphoma in mice.

      Pérez-Chacón G, Llobet D, Pardo C, Pindado J, Choi Y, Reed JC, Zapata JM

      Journal of Immunology. 189:1053-61. 2012

    • ERα-mediated repression of pro- inflammatory cytokine expression by glucocorticoids reveals a critical role for TNFα and IL1α in lumen formation and maintenance.

      Eritja N, Mirantes C, Llobet D, Masip G, Matias-Guiu X, Dolcet X

      Journal of Cell Science. 125:1929-44. 2012

    • Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma.

      Montserrat N, Mozos A, Llobet D, Dolcet X, Pons C, de Herreros AG, Matias-Guiu X, Prat J

      Human Pathology. 43:632-43. 2012

    • KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels.

      Llobet D, Eritja N, Domingo M, Bergada L, Mirantes C, Santacana M, Pallares J, Macià A,Yeramian A, Encinas M, Moreno-Bueno G, Palacios J, Lewis RE, Matias-Guiu X, Dolcet X

      American Journal of Pathology. 178:1529-1543. 2011

    • An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma.

      Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer A, Llobet-Navas D, Rajbhandari P, Bansal M, Guarnieri P, Silva J, Califano A

      Cell. 147:370-81. 2011

    • Nuclear factor-Kappa B2/p100 promotes Endometrial Carcinoma cell survival under hypoxia in a HIF-1α independent manner.

      Yeramian A, Santacana M, Sorolla A, Llobet D, Encinas M, Velasco A, Bahi N, Eritja N, Domingo M, Dolcet X, Oliva E, Matias-Guiu X

      Laboratory Investigation. 91:859-71. 2011

    • The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.

      Llobet D, Eritja N, Yeramian A, Pallares J, Sorolla A, Domingo M, Santacana M, Gonzalez-Tallada FJ, Matias-Guiu X, Dolcet X

      European Journal Of Cancer. 46:836-850. 2010

    • A novel 3D culture system of polarized epithelial cells to study endometrial carcinogenesis.

      Eritja N, Llobet D, Domingo M, Yeramian A, Matias-Guiu X, Dolcet X

      American Journal of Pathology. 176:2722-31. 2010

    • DcR1 expression in endometrial carcinomas.

      Tarragona J, Llecha N, Santacana M, Lopez S, Gatius S, Llobet D, Dolcet X, Palomar-Asenjo V, González-Tallada FJ, Matias-Guiu X

      Virchows Archiv. 456:39-44. 2010

    • CK2β is expressed in endometrial carcinoma, and has a role in apoptosis resistance and cell proliferation.

      Pallarés J*, Llobet D*, Santacana M, Eritja N, Puente S, López S, Palomar-Asenjo V, Yeramian A, Dolcet X, Matias-Guiu X

      American Journal of Pathology. 174:287-96. 2009

    • Molecular pathology of endometrial carcinoma; practical aspects from the diagnostic and therapeutical viewpoints.

      Llobet D, Pallarés J, Yeramian A, Santacana M, Eritja N, Velasco A, Dolcet X, Matias-Guiu X

      Journal of Clinical Pathology. 62:777-85. 2009

    • Lymphocyte-specific TRAF3-transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer.

      Zapata JM, Llobet D, Krajewska M, Lefebvre S, Kress CL, Reed JC

      Blood. 113:4595-603. 2009

    • A review of the applications of tissue microarray technology in understanding the molecular features of endometrial carcinoma.

      Pallares J, Santacana M, Puente S, Lopez S, Yeramian A, Eritja N, Sorolla A, Llobet D, Dolcet X, Matias-Guiu X

      Analytical and Quantitative Cytology and Histology. 31:217-26. 2009

    • CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells.

      Llobet D, Eritja N, Encinas M, Llecha N, Yeramian A, Pallarés J, Sorolla A, González-Tallada FJ, Matias-Guiu X

      Oncogene. 27:2513-24. 2008

    • Antioxidants block proteasome inhibitors function in endometrial carcinoma cells.

      Llobet D, Eritja N, Sorolla A, Yeramian A, Schoenenberger JA, Llombart-Cussac A, Martí RM, Matias-Guiu X, Dolcet X

      Anti-Cancer Drugs. 19:115-124. 2008

    • Nuclear factor–kB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma.

      Gallel P, Pallarés J, Dolcet X, Llobet D, Eritja N, Santacana M, Yeramian A, Palomar-Asenjo V, Lagarda H, Mauricio D, Encinas M, Matias-Guiu X

      Human Pathology. 39:994-1001. 2008

    • Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines.

      Sorolla A, Yeramian A, Dolcet X, Pérez de Santos AM, Llobet D, Schoenenberger JA, Casanova JM, Soria X, Egido R, Llombart A, Vilella R, Matias-Guiu X, Martí RM

      British Journal of Dermatology. 158:496-504. 2008

    • Targeted therapies in gynecologic cancers and melanoma.

      Ortega E, Marti RM, Yeramian A, Sorolla A, Dolcet X, Llobet D, Abal L, Santacana M, Pallares J, Llombart-Cussac A, Matias-Guiu X

      Seminars in Diagnostic Pathology. 25:262-73. 2008

    • Proteasome inhibitors induce death but activate NF-kappa B on endometrial carcinoma cell lines and primary culture explants.

      Dolcet X*, Llobet D*, Encinas M, Pallarés J, Cabero A, Schoenenberger JA, Comella JX, Matias- Guiu X

      Journal of Biological Chemistry. 281:22118- 30. 2006

    • PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.

      Velasco A, Bussaglia E, Pallarés J, Dolcet X, Llobet D, Encinas M, Llecha N, Palacios J, Prat J, Matias-Guiu X

      Human Pathology. 37:1465-72. 2006

    • Flip is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis.

      Dolcet X, Llobet D, Pallarés J, Comella JX, Matias-Guiu X

      Laboratory Investigation. 85:885-94. 2005

    • NF-KappaB in development and progression.

      Dolcet X, Llobet D, Pallarés J, Matias-Guiu X

      Virchows Archiv. 446:475-82. 2005

    • Survivin expression in endometrial carcinoma. A tissue microarray study with correlation with PTEN and STAT3.

      Pallarés J, Martínez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J, Matias-Guiu X

      International Journal of Gynecological Pathology. 24:247-53. 2005

    • Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities.

      Pallarés J, Bussaglia E, Martínez-Guitarte JL, Dolcet X, Llobet D, Rue M, Sanchez-Verde L, Palacios J, Prat J, Matias-Guiu X

      Modern Pathology. 18:719-27. 2005

    • Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma.

      Pallarés J, Martínez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J, Matias-Guiu X

      Journal of Pathology. 204:569-77. 2004